Sex hormone pathway gene polymorphisms are associated with risk of advanced hepatitis c-related liver disease in males

International Journal of Molecular Epidemiology and Genetics

Volumn 5, Issue 3, 2014, Pages 164-176

  White, Donna L ^a,b,c   Liu, Yanhong ^c   Garcia, Jose ^a,c   El Serag, Hashem B ^a,b,c   Jiao, L ^a,b,c   Tsavachidis, Spiridon ^c   Franco, Luis M ^c   Lee, Ju Seog ^d   Tavakoli Tabasi, Shahriar ^a   Moore, David ^c   Goldman, Radoslav ^e   Kuzniarek, Jill ^a   Ramsey, David J ^a   Kanwal, Fasiha ^a,b,c   Marcelli, Marco ^a  

^a MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b EAST TEXAS MEDICAL CENTER   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Carcinogenesis; Digestive system; Endocrinology; Epidemiology; Genetics; Hepatology; Infectious diseases

Indexed keywords

ANDROGEN; ESTROGEN; ESTROGEN RECEPTOR ALPHA; STEROID 5ALPHA REDUCTASE 1; TESTOSTERONE 17BETA DEHYDROGENASE;

ADULT; AGE; AKR1C2 GENE; AKR1C3 GENE; ALCOHOL ABUSE; ARTICLE; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; DISEASE COURSE; DNA POLYMORPHISM; ETHNICITY; GENE; GENE LOCUS; GENETIC ASSOCIATION; GENOTYPE ENVIRONMENT INTERACTION; GENOTYPING TECHNIQUE; HAPLOTYPE; HEALTH SURVEY; HEPATITIS C; HORMONE SYNTHESIS; HUMAN; INFLAMMATION; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTIFACTOR DIMENSIONALITY REDUCTION; OBESITY; OUTCOME ASSESSMENT; PHENOTYPE; PROSPECTIVE STUDY; SENSITIVITY ANALYSIS; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; VIRUS LOAD;

EID: 84908218466     PISSN: None     EISSN: 19481756     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL and Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006; 144: 705-714.
2. Centers for Disease Control and Prevention. The ABCs of hepatitis. 2012.
3. Heron M, Xu J and Kochanek KD. Deaths: Final data for 2010. Natl Vital Stat Rep 2013; 61: 1-168.
4. Wiesner RH, Sorrell M, Villamil F; Inter-national Liver Transplantation Society. Report of the first International Liver Transplantation Society expert panel consensus conference on liver transplantation and hepatitis C. Liver Transpl 2003; 9: S1-S9.
5. Fattovich G, Stroffolini T, Zagni I and Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004; 127: S35-S50.
6. Hayashida K, Shoji I, Deng L, Jiang DP, Ide YH and Hotta H. 17beta-estradiol inhibits the production of infectious particles of hepatitis C virus. Microbiol Immunol 2010; 54: 684-690.
7. Nguyen HV, Mollison LC, Taylor TW, Chubb SA and Yeap BB. Chronic hepatitis C infection and sex hormone levels: effect of disease severity and recombinant interferon-alpha therapy. Intern Med J 2006; 36: 362-366.
8. White DL, Tavakoli-Tabasi S, Kuzniarek J, Pascua R, Ramsey DJ and El-Serag HB. Higher serum testosterone is associated with increased risk of advanced hepatitis C-related liver disease in males. Hepatology 2012; 55: 759-768.
9. Villa E, Vukotic R, Camma C, Petta S, Di LA, Gitto S, Turola E, Karampatou A, Losi L, Bernabucci V, Cenci A, Tagliavini S, Baraldi E, De MN, Gelmini R, Bertolini E, Rendina M and Francavilla A. Reproductive status is associated with the severity of fibrosis in women with hepatitis C. PLoS One 2012; 7: e44624.
10. Chang KH, Li R, Kuri B, Lotan Y, Roehrborn CG, Liu J, Vessella R, Nelson PS, Kapur P, Guo X, Mirzaei H, Auchus RJ and Sharifi N. A gain-of-function mutation in DHT synthesis in castration-resistant prostate cancer. Cell 2013; 154: 1074-1084.
11. Rossi L, Leveri M, Gritti C, De SA, Zavaglia C, Sonzogni L, Silvestri L, Civardi E, Mondelli MU and Silini EM. Genetic polymorphisms of steroid hormone metabolizing enzymes and risk of liver cancer in hepatitis C-infected patients. J Hepatol 2003; 39: 564-570.
12. Poynard T, Moussalli J, Munteanu M, Thabut D, Lebray P, Rudler M, Ngo Y, Thibault V, Mkada H, Charlotte F, Bismut FI, Deckmyn O, Benhamou Y, Valantin MA, Ratziu V and Katlama C. Slow regression of liver fibrosis presumed by repeated biomarkers after virological cure in patients with chronic hepatitis C. J Hepatol 2013; 59: 675-683.
13. White DL, Tavakoli-Tabasi S, Kuzniarek J, Ramsey DJ and El-Serag HB. Racial differences in the association between adiposity measures and the risk of hepatitis C-related liver disease. J Clin Gastroenterol 2012; 46: 779-788.
14. Patel K, Benhamou Y, Yoshida EM, Kaita KD, Zeuzem S, Torbenson M, Pulkstenis E, Subramanian GM and McHutchison JG. An independent and prospective comparison of two commercial fibrosis marker panels (HCV FibroSURE and FIBROSpect II) during albinterferon alfa-2b combination therapy for chronic hepatitis C. J Viral Hepat 2009; 16: 178-186.
15. Poynard T, de Ledinghen V, Zarski JP, Stanciu C, Munteanu M, Vergniol J, France J, Trifan A, Le Naour G, Vaillant JC, Ratziu V, Charlotte F; Fibrosis-TAGS group. Relative performances of FibroTest, Fibroscan, and biopsy for the assessment of the stage of liver fibrosis in patients with chronic hepatitis C: a step toward the truth in the absence of a gold standard. J Hepatol 2012; 56: 541-548.
16. Halfon P, Bourliere M, Deydier R, Botta-Fridlund D, Renou C, Tran A, Portal I, Allemand I, Bertrand JJ, Rosenthal-Allieri A, Rotily M, Sattonet C, Benderitter T, Saint Paul MC, Bonnot HP, Penaranda G, Degott C, Masseyeff MF and Ouzan D. Independent prospective multicenter validation of biochemical markers (fibrotest-actitest) for the prediction of liver fibrosis and activity in patients with chronic hepatitis C: the fibropaca study. Am J Gastroenterol 2006; 101: 547-555.
17. Said Y, Salem M, Mouelhi L, Mekki H, Houissa F, Ben RM, Moussa A, Trabelsi S, Debbeche R, Bouzaidi S and Najjar T. Correlation between liver biopsy and fibrotest in the evaluation of hepatic fibrosis in patients with chronic hepatitis C. Tunis Med 2010; 88: 573-578.
18. Aikake H. A new look at the statistical model identification. IEEE Trans Automat Contr 1974; 19: 716-723.
19. Wacholder S, Chanock S, Garcia-Closas M, El GL and Rothman N. Assessing the probability that a positive report is false: an approach for molecular epidemiology studies. J Natl Cancer Inst 2004; 96: 434-442.
20. Hahn LW, Ritchie MD and Moore JH. Multifactor dimensionality reduction software for detecting gene-gene and gene-environment interactions. Bioinformatics 2003; 19: 376-382.
21. Ritchie MD, Hahn LW, Roodi N, Bailey LR, Dupont WD, Parl FF and Moore JH. Multifactor-dimensionality reduction reveals high-order interactions among estrogen-metabolism genes in sporadic breast cancer. Am J Hum Genet 2001; 69: 138-147.
22. Lewontin RC. On measures of gametic disequilibrium. Genetics 1988; 120: 849-852.
23. Schaid DJ, Rowland CM, Tines DE, Jacobson RM and Poland GA. Score tests for association between traits and haplotypes when linkage phase is ambiguous. Am J Hum Genet 2002; 70: 425-434.
24. Yepuru M, Wu Z, Kulkarni A, Yin F, Barrett CM, Kim J, Steiner MS, Miller DD, Dalton JT and Narayanan R. Steroidogenic enzyme AKR1C3 is a novel androgen receptor-selective coactivator that promotes prostate cancer growth. Clin Cancer Res 2013; 19: 5613-5625.
25. Stanbrough M, Bubley GJ, Ross K, Golub TR, Rubin MA, Penning TM, Febbo PG and Balk SP. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res 2006; 66: 2815-2825.
26. Liedtke AJ, Adeniji AO, Chen M, Byrns MC, Jin Y, Christianson DW, Marnett LJ and Penning TM. Development of potent and selective indomethacin analogues for the inhibition of AKR1C3 (Type 5 17beta-hydroxysteroid dehydrogenase/prostaglandin F synthase) in castrate-resistant prostate cancer. J Med Chem 2013; 56: 2429-2446.
27. Kwon EM, Holt SK, Fu R, Kolb S, Williams G, Stanford JL and Ostrander EA. Androgen metabolism and JAK/STAT pathway genes and prostate cancer risk. Cancer Epidemiol 2012; 36: 347-353.
28. Figueroa JD, Malats N, Garcia-Closas M, Real FX, Silverman D, Kogevinas M, Chanock S, Welch R, Dosemeci M, Lan Q, Tardon A, Serra C, Carrato A, Garcia-Closas R, Castano-Vinyals G and Rothman N. Bladder cancer risk and genetic variation in AKR1C3 and other metabolizing genes. Carcinogenesis 2008; 29: 1955-1962.
29. Blouin K, Blanchette S, Richard C, Dupont P, Luu-The V and Tchernof A. Expression and activity of steroid aldoketoreductases 1C in omental adipose tissue are positive correlates of adiposity in women. Am J Physiol Endocrinol Metab 2005; 288: E398-E404.
30. Wake DJ, Strand M, Rask E, Westerbacka J, Livingstone DE, Soderberg S, Andrew R, Yki-Jarvinen H, Olsson T and Walker BR. Intra-adipose sex steroid metabolism and body fat distribution in idiopathic human obesity. Clin Endocrinol (Oxf) 2007; 66: 440-446.
31. Yan Z, Tan W, Xu B, Dan Y, Zhao W, Deng C, Chen W, Tan S, Mao Q, Wang Y and Deng G. A cis-acting regulatory variation of the estrogen receptor alpha (ESR1) gene is associated with hepatitis B virus-related liver cirrhosis. Hum Mutat 2011; 32: 1128-1136.
32. Dowman JK, Hopkins LJ, Reynolds GM, Armstrong MJ, Nasiri M, Nikolaou N, van Houten EL, Visser JA, Morgan SA, Lavery GG, Oprescu A, Hubscher SG, Newsome PN and Tomlinson JW. Loss of 5alpha-reductase type 1 accelerates the development of hepatic steatosis but protects against hepatocellular carcinoma in male mice. Endocrinology 2013; 154: 4536-4547.
33. White DL, Hashmi A, Ramsey DJ, Kuzniarek J, Tavakoli-Tabasi S and El-Serag HB. Finasteride and methadone use and risk of advanced hepatitis C related liver disease. Dig Dis Sci 2012; 57: 3004-3010.
34. Poynard T, Lenaour G, Vaillant JC, Capron F, Munteanu M, Eyraud D, Ngo Y, M’Kada H, Ratziu V, Hannoun L and Charlotte F. Liver biopsy analysis has a low level of performance for diagnosis of intermediate stages of fibrosis. Clin Gastroenterol Hepatol 2012; 10: 657-663.